Arnfin Bergmann

Statistics

Publications

Citations

1.5K

H-Index

Active since

1983

Affiliations

Hasselt University(Current)

KU Leuven

University Hospital of Basel

Klinik Donaustauf

Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno

Arnfin Bergmann is an author at Hasselt University specializing in multiple sclerosis, medicine, and relapsing-remitting multiple sclerosis treatment.

Publications per year

1983–2022

Publications

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

COVID-19 in people with multiple sclerosis: A global data sharing initiative

Liesbet M. Peeters, Tina Parciak, Clare Walton et al. · Multiple Sclerosis Journal · 2020 · 63 citations · Full text

Computing, Biomedical Informatics, Health Informatics +14

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

Stefan Braune, Sarah Grimm, Philip van Hövell et al. · Journal of Neurology · 2018 · 59 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +17

Updated Results of the COVID-19 in MS Global Data Sharing Initiative

Steve Simpson, Ashkan Pirmani, Tomáš Kalinčík et al. · Neurology Neuroimmunology & Neuroinflammation · 2022 · 53 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +13

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

Stefan Braune, Michael Lang, Arnfin Bergmann · Journal of Neurology · 2013 · 44 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +15

1–5 of 19